Week 2026-W27

Advances presented at AACR 2026 highlight a shift towards integrated, agentic artificial intelligence (AI) systems in oncology. Platforms like Synapse facilitate large-scale data coordination, while conversational and multi-agent tools enable simplified interaction with multimodal cancer data. AI demonstrates high accuracy and scalability for real-world data transformation, including clinical document abstraction and social determinants of health analysis. Clinically, it enhances imaging biomarkers, trial matching, and cohort identification, while also accelerating therapeutic discovery, including CAR-T development and immunotherapy target identification.

This study characterized the genomic landscape of leiomyosarcoma, a rare and aggressive tumor, by analyzing a large dataset from the AACR Project GENIE. Researchers examined over 1,000 tumor samples, identifying the most frequent somatic mutations and copy number alterations. TP53, RB1, and ATRX were the most commonly altered genes, with homozygous deletions of RB1 and TP53, and MAP2K4 amplifications. The study also highlighted enriched IGF2 and AXIN1 alterations in metastatic samples, suggesting their potential role in disease progression. These findings enhance the understanding of leiomyosarcoma biology and could guide future precision oncology strategies.

This study investigated the role of the LMBR1L protein in gastric cancer, revealing its significant overexpression in tumor tissues. Patients with high LMBR1L levels exhibited reduced postoperative overall and disease-free survival rates. Multivariate analyses confirmed LMBR1L expression as an independent risk factor for gastric cancer patient prognosis. Furthermore, a nomogram model incorporating LMBR1L demonstrated good predictive value for postoperative survival. In vivo experiments also indicated that LMBR1L knockdown significantly inhibits tumor growth.